EVH Stock Analysis: Evolent Health | NYSE

Health Information Services | NYSE, USA | Market Cap: 554m USD | 12M Return: 19.4% | US30050B1017 | Charts, Fundamentals & Technical Analysis

Specialty Management, Value-Based Care, Administrative Support, Prior Authorization
Total Rating 34
Safety 30
Buy Signal -0.41
Health Care Technology
Sub-Industry Rotation: -22.8
Market Cap: 554M
Avg Turnover: 7.44M
Risk 3d forecast
Volatility75.9%
VaR 5th Pctl11.0%
VaR vs Median-8.85%
Reward TTM
Sharpe Ratio0.56
Rel. Str. IBD88.2
Rel. Str. Peer Group67.9 pctl
Character TTM
Beta1.201
Beta Downside1.617
Hurst Exponent0.689
Choppyness77.1%
Drawdowns 3y
Max DD93.75%
CAGR/Max DD-0.49
CAGR/Mean DD-0.76
EPS (Earnings per Share) EPS (Earnings per Share) of EVH over the last years for every Quarter: "2021-09": -0.03, "2021-12": 0.08, "2022-03": 0.12, "2022-06": 0.1, "2022-09": 0.59, "2022-12": 0.1, "2023-03": 0.21, "2023-06": 0.14, "2023-09": 0.3, "2023-12": 0.23, "2024-03": 0.34, "2024-06": 0.3, "2024-09": 0.04, "2024-12": -0.02, "2025-03": 0.06, "2025-06": -0.17, "2025-09": 0.05, "2025-12": 0.08, "2026-03": -0.02, "2026-06": -0.11, "2026-09": -0.04,
Last SUE: 0.08
Qual. Beats: 0
Revenue Revenue of EVH over the last years for every Quarter: 2021-09: 222.471, 2021-12: 248.358, 2022-03: 297.057, 2022-06: 319.939, 2022-09: 352.585, 2022-12: 382.432, 2023-03: 427.69, 2023-06: 469.136, 2023-09: 511.015, 2023-12: 556.055, 2024-03: 639.653, 2024-06: 647.145, 2024-09: 621.401, 2024-12: 646.542, 2025-03: 483.649, 2025-06: 444.328, 2025-09: 479.533, 2025-12: 468.719, 2026-03: 496.246, 2026-06: 652.52, 2026-09: 725.367,
Rev. CAGR: -2.81%
Rev. Trend: -24.7%
Last SUE: -0.06
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Choppy
Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 11.4 years of data, until 10/2026

Jan +1.6% 0
Feb +4.8% 9
Mar -0.3% 0
Apr +12.0% 21
May -2.7% 9
Jun +1.8% 9
Jul +1.3% 4
Aug +2.8% 14
Sep -0.1% 0
Oct -11.2% 47
Nov -12.0% 9
Dec -3.3% 9

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: EVH Evolent Health

Evolent Health, Inc. is a U.S.-based specialty care management company that operates an integrated value-based care platform serving health plans across oncology, cardiology, and musculoskeletal markets. The company combines administrative services-including health plan management, pharmacy benefits management, risk management, and analytics-with proprietary technology, notably its Identifi system for data aggregation and care workflow management, and Machinify Auth Intelligence, an AI tool that supports prior authorization clinical review. Headquartered in Arlington, Virginia, Evolent was founded in 2011 and serves as an intermediary between payers and providers, focusing on high-cost, complex specialty conditions.

Within the Health Care Technology sub-industry, Evolent operates in the value-based care space, a payment and delivery model in which providers are reimbursed based on patient health outcomes and total cost of care rather than the volume of services rendered. Specialty care management-a core focus of the company-targets conditions that typically account for a disproportionate share of healthcare spending, making analytics-driven platforms and prior authorization tools central to payer cost-containment strategies.

Headlines to Watch Out For
  • Oncology and cardiology segment revenue growth accelerates
  • Integration costs continue pressuring operating margins
  • Prior authorization regulatory shifts shape Machinify AI demand
Piotroski VR-10 (Strict) 4.0
Net Income: -507.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 4.29 > 1.0
NWC/Revenue: 5.43% < 20% (prev 6.82%; Δ -1.40% < -1%)
CFO/TA 0.03 > 3% & CFO 63.9m > Net Income -507.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.26 > 1.5 & < 3
Outstanding Shares: last quarter (113.1m) vs 12m ago -0.87% < -2%
Gross Margin: 12.10% > 18% (prev 16.11%; Δ -4.02% > 0.5%)
Asset Turnover: 106.1% > 50% (prev 83.72%; Δ 22.40% > 0%)
Interest Coverage Ratio: -6.24 > 6 (EBIT TTM -434.9m / Interest Expense TTM 69.7m)
Altman Z'' -2.97
A: 0.06 (Total Current Assets 617.1m - Total Current Liabilities 489.9m) / Total Assets 1.96b
B: -0.71 (Retained Earnings -1.39b / Total Assets 1.96b)
C: -0.20 (EBIT TTM -434.9m / Avg Total Assets 2.21b)
D: 0.23 (Book Value of Equity 372.9m / Total Liabilities 1.59b)
Altman-Z'' = -2.97 = D
Beneish M -2.73
DSRI: 1.00 (Receivables 442.8m/386.6m, Revenue 2.34b/2.05b)
GMI: 1.33 (GM 16.11% / 12.10%)
AQI: 0.88 (AQ_t 0.64 / AQ_t-1 0.73)
SGI: 1.14 (Revenue 2.34b / 2.05b)
TATA: -0.29 (NI -507.7m - CFO 63.9m) / TA 1.96b)
Beneish M = -2.73 (Cap -4..+1) = A
What is the price of EVH shares?

As of November 18, 2026, the stock is trading at USD 4.62 with a total of 1,479,601 shares traded. Over the past week, the price has changed by -3.75%, over one month by +3.12%, over three months by +4.76% and over the past year by +19.38%.

Current recommended Stop Loss: 4.00 (which is 13.4% or 1.9 ATR below the current price).

Is EVH a buy, sell or hold?

Evolent Health has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy EVH.

  • StrongBuy: 7
  • Buy: 4
  • Hold: 3
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the EVH price?
Analysts Target Price 5.9 28.1%
Evolent Health (EVH) - Fundamental Data Overview as of 15 November 2026
Market Cap USD = 554.2m (554.2m USD * 1.0 USD.USD)
P/E Forward = 11.3507
P/S = 0.2366
P/B = 1.447
P/EG = 1.9281
Revenue TTM = 2.34b USD
EBIT TTM = -434.9m USD
EBITDA TTM = -324.3m USD
Long Term Debt = 969.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.32m USD (from shortTermDebt, last quarter)
Debt = 976.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.57m
Net Debt = 828.4m USD (calculated: Debt 976.6m - CCE 148.3m)
Enterprise Value = 1.38b USD (554.2m + Debt 976.6m - CCE 148.3m)
Interest Coverage Ratio = -6.24 (Ebit TTM -434.9m / Interest Expense TTM 69.7m)
EV/FCF = 47.24x (Enterprise Value 1.38b / FCF TTM 29.3m)
FCF Yield = 2.12% (FCF TTM 29.3m / Enterprise Value 1.38b)
FCF Margin = 1.25% (FCF TTM 29.3m / Revenue TTM 2.34b)
Net Margin = -21.67% (Net Income TTM -507.7m / Revenue TTM 2.34b)
Gross Margin = 12.10% ((Revenue TTM 2.34b - Cost of Revenue TTM 2.06b) / Revenue TTM)
Gross Margin QoQ = 12.19% (prev 12.39%)
Tobins Q-Ratio = 0.70 (Enterprise Value 1.38b / Total Assets 1.96b)
Interest Expense / Debt = 7.14% (Interest Expense 69.7m / Debt 976.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -343.6m (EBIT -434.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.26 (Total Current Assets 617.1m / Total Current Liabilities 489.9m)
Debt / Equity = 2.62 (Debt 976.6m / totalStockholderEquity, last quarter 372.9m)
 Debt / EBITDA = -2.55 (negative EBITDA) (Net Debt 828.4m / EBITDA -324.3m)
 Debt / FCF = 28.30 (Net Debt 828.4m / FCF TTM 29.3m)
Total Stockholder Equity = 391.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.00% (Net Income -507.7m / Total Assets 1.96b)
RoE = -129.5% (Net Income TTM -507.7m / Total Stockholder Equity 391.9m)
RoCE = -31.94% (EBIT -434.9m / Capital Employed (Equity 391.9m + L.T.Debt 969.5m))
 RoIC = -25.33% (negative operating profit) (NOPAT -343.6m / Invested Capital 1.36b)
 WACC = 7.10% (E(554.2m)/V(1.53b) * Re(9.67%) + D(976.6m)/V(1.53b) * Rd(7.14%) * (1-Tc(0.21)))
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.96 | Cagr: -0.63%
[DCF] Terminal Value 75.44% ; FCFF base≈29.3m ; Y1≈29.4m ; Y5≈31.1m
 [DCF] Fair Price = N/A (negative equity: EV 484.2m - Net Debt 828.4m = -344.2m; debt exceeds intrinsic value)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.08 | # QB: 0
Revenue Correlation: -24.66 | Revenue CAGR: -2.81% | SUE: -0.06 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.07 | Chg30d=-5.14% | Revisions=-17% | Analysts=6
EPS current Year (2026-12-31): EPS=0.24 | Chg30d=+18.46% | Revisions=+40% | GrowthEPS=+163.1% | GrowthRev=+40.8%
EPS next Year (2027-12-31): EPS=0.42 | Chg30d=+4.70% | Revisions=+25% | GrowthEPS=+78.6% | GrowthRev=+25.7%
[Analyst] Revisions Ratio: +22% (up=4, down=2)